The CRL was fully anticipated and does not change the fundamental regulatory path. The key catalyst is the NDA resubmission in Q4 2026 and the subsequent FDA review cycle. Monitor for any updates on the manufacturing transition to Adare and the timing of the resubmission. The stock will likely trade on regulatory milestones rather than quarterly financials.
Price Chart
Executive Summary
Achieve Life Sciences reported Q2 2026 financial results, highlighting a net loss of $74.8M for the quarter (including a $48.7M non-cash warrant liability charge) and ending cash of $187.3M. The company reiterated its plan to resubmit the NDA for cytisinicline in Q4 2026, with potential FDA approval in H1 2027. The CRL received in June 2026 was expected and relates only to manufacturing, not efficacy or safety, keeping the core regulatory timeline intact.
Key Financial Metrics
Key Facts
- Cash, cash equivalents, and marketable securities were $187.3M as of June 30, 2026, up from $29.3M at March 31, 2026, reflecting the $180M upfront private placement.
- Net loss for Q2 2026 was $74.8M, including a $48.7M non-cash charge for the change in fair value of warrant liabilities.
- Total operating expenses for Q2 2026 were $18.4M, up from $12.6M in Q2 2025, driven by increased G&A costs ($14.6M vs $5.9M).
- The company received a Complete Response Letter (CRL) on June 20, 2026, related to cGMP observations at the prior manufacturer, not clinical efficacy or safety.
- The company plans to resubmit the NDA in Q4 2026, naming Adare Pharma Solutions as the new manufacturer, with potential FDA approval in H1 2027.
- The private placement of up to $354M ($180M upfront) was closed, with proceeds to fund the ORCA-V2 Phase 3 trial and commercialization.
Financial Impact
Q2 2026 net loss of $74.8M includes a $48.7M non-cash warrant liability charge; operating cash burn was $18.4M for the quarter. Cash position of $187.3M provides runway through potential FDA approval and launch.
Risk Factors
- Risk of further delays in NDA resubmission or FDA approval beyond H1 2027.
- Risk of additional cGMP issues at the new manufacturer Adare Pharma Solutions.
- Risk of dilutive warrant exercises (up to $174M) prior to or following FDA approval.
- Risk of commercial launch execution failure given the company is pre-revenue and building a commercial team from scratch.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-344571 |
| Document: achv-20260811.htm | 0001193125-26-344571 |
| Document: 0001193125-26-344571-index-headers.html | 0001193125-26-344571 |
| Document: 0001193125-26-344571-index.html | 0001193125-26-344571 |
| Document: 0001193125-26-344571.txt | 0001193125-26-344571 |
| 8-K Data (Synthetic) | 0001193125-26-344571 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | 3 | $7.24 $7.19 | ▼ −0.69% | ▼ −0.27% | $6.74 (−6.91%) |
Oct 1, 2026 25d ago | 8-K | $7.24 $7.01 | ▼ −3.18% | ▼ −3.85% | $6.74 (−6.91%) |
Aug 14, 2026 10w ago | 8-K | $7.50 $7.52 | ▼ −0.27% | ▼ −0.94% | $6.74 (+10.13%) |
Aug 11, 2026 10w ago | 8-K | $6.69 $7.25 | ▲ +8.37% | ▲ +7.67% | $6.74 (+0.75%) |
Aug 11, 2026 11w ago | Press Release | $6.77 $6.69 | ▲ +1.18% | ▲ +1.43% | $6.74 (+0.44%) |
Aug 7, 2026 11w ago | Institutional Cluster | $6.65 $6.67 | ▲ +0.30% | ▲ +0.33% | $6.74 (+1.35%) |
Jun 11, 2026 19w ago | Institutional Cluster | $5.52 $5.52 | · 0.00% | ▲ +0.54% | $6.74 (−22.10%) |
Jun 2, 2026 21w ago | 8-K | $5.03 $4.92 | ▼ −2.19% | ▼ −1.49% | $6.74 (+34.00%) |
May 22, 2026 22w ago | EFFECT | $4.69 $4.56 | ▲ +2.77% | ▲ +3.36% | $6.74 (−43.71%) |
May 19, 2026 22w ago | Press Release | $4.45 $4.57 | ▲ +2.70% | ▲ +1.66% | $6.74 (+51.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers